NSAID-gastroenteropathy: new aspects of pathogenesis and prevention

Rory W Blackler; Burcu Gemici; Anna Manko; John L Wallace

doi:10.1016/j.coph.2014.05.008

NSAID-gastroenteropathy: new aspects of pathogenesis and prevention

Curr Opin Pharmacol. 2014 Dec:19:11-6. doi: 10.1016/j.coph.2014.05.008. Epub 2014 Jun 13.

Authors

Rory W Blackler¹, Burcu Gemici², Anna Manko¹, John L Wallace³

Affiliations

¹ Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
² Near East University, Nicosia, Cyprus.
³ Department of Physiology & Pharmacology, University of Calgary, Calgary, Alberta, Canada; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada. Electronic address: altapharm@hotmail.com.

PMID: 24929967
DOI: 10.1016/j.coph.2014.05.008

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) remain among the most commonly used medications because of their effectiveness in reducing pain and inflammation. Inhibitors of gastric acid secretion can substantially reduce the damaging effects of NSAIDs in the stomach and duodenum. However, there are no proven effective preventative or curative treatments for NSAID-induced enteropathy. In recent years, substantial progress has been made in better understanding the pathogenesis of NSAID-enteropathy, and in particular the interplay of enteric bacteria, bile and the enterohepatic recirculation of the NSAIDs. Moreover, it is becoming clear that suppression of gastric acid secretion significantly worsens NSAID-enteropathy.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
Gastrointestinal Diseases / chemically induced*
Gastrointestinal Diseases / metabolism
Gastrointestinal Diseases / prevention & control*
Humans
Proton Pump Inhibitors / adverse effects
Proton Pump Inhibitors / therapeutic use

Substances

Anti-Inflammatory Agents, Non-Steroidal
Proton Pump Inhibitors

Grants and funding

Canadian Institutes of Health Research/Canada